written on 16.06.2014

Could Pfizer nab AstraZeneca with pipeline-based payouts? Maybe, but cash is easier


When Sanofi bought Genzyme, the deal was clinched on a contingent value right (CVR) based on the potential multiple sclerosis treatment Lemtrada. Could Pfizer do the same thing to win over AstraZeneca?

Latest Reports